金斯瑞生物科技2025年度报告

Make people and nature healthierthrough biotechnology. (Incorporated in the Cayman Islands with limited liability)Stock code: 1548 (i)(ii)CRDMOCGT(iii)DNARNACGT 目錄 公司概況 (i)(ii)CRDMOCGT(iii) 202512311006,165 DNARNA CRDMOCGTCGT ESG John Quelch John Quelch Alphonse GaldesJohn QuelchRoss Grossman Alphonse Galdes 20263152026315 Ross Grossman 1191904 ESG 公司資料 183171712–1716 97927 www.genscript.comwww.probiocdmo.comwww.bestzyme.com 4th Floor, Harbour Place103 South Church Street, George TownP.O. Box 10240, Grand Cayman KY1-1002Cayman Islands 860 Centennial AvenuePiscatawayNJ 08854U.S. 1548 24840 Harneys Services (Cayman) Limited4th Floor, Harbour Place103 South Church StreetGeorge TownP.O. Box 10240, Grand Cayman KY1-1002Cayman Islands 財務亮點 •959.561.4% •553.2103.3% 230.3285.0% 532.429 •320.4188.833.1 •398.1 32 (2)(i)(ii)(iii)(iv)(v)(vi)(vii)(viii)(ix) (3)https://investors.legendbiotech.com/press-releases20251231 五年財務摘要 主席致辭 2025AI 2025 2025 CRDMOCMCGMP AI 2026AI2026 主席致辭 CARVYKTI®2025CARVYKTI®10,000(MM) 2026315 管理層討論及分析 (i) (ii)CRDMOCGT (iii) 100202512316,165 DNARNA CRDMOCGTCGT 管理層討論及分析 959.5594.561.4%553.2272.1103.3%(i)(ii)(iii)AI(iv)CRDMO(v) 532.429320.4398.1230.359.8285.0% 532.83032 (i)(ii)(iii)53.8%39.8%6.0% 金斯瑞生命科學事業群－生命科學服務及產品 DNA 業績 522.1454.914.8%267.3237.712.5%51.2%52.2%90.45.5%95.4 (i)(ii)(iii) 管理層討論及分析 發展策略 (i)(ii)(iii)(iv) 蓬勃生物－生物製劑開發服務 CRDMODNARNA 業績 388.795.0309.1%258.414.415.1%66.5%194.043.4 (i)(ii)CMC(iii) 發展策略 (i)(ii)(iii) 管理層討論及分析 NMECD3TCENME 百斯傑－工業合成生物產品 業績 58.053.77.9%23.022.642.1%39.6%3.22.1 (i)(ii)(iii) 發展策略 (i)(ii)(iii) ESG ESGESG 2023(UNGC)2025(PSCI)(SBTi)EcoVadisMSCI ESGAASustainalyticsESG2026 金斯瑞商業系統 202579(Kaizen) 管理層討論及分析 2025959.52024594.561.4%(i)(ii)(iii)AI(iv)CRDMO(v) 20252024272.1103.3%553.298.6% 2025202488.112.9%99.5(i)(ii)14.6% 20252024114.412.4%128.6(i)(ii)14.8% 2025202453.832.4%71.232.8% 管理層討論及分析 2021818ProBio CaymanProBio Cayman300,000,000A189,393,939ProBio CaymanProBio Cayman150.0ProBio Cayman125.0ProBio Cayman2025428AA14.4202151420216720218192021952025428202557 2023117ProBio CaymanProBio Cayman319,998,370C224.0202311720232102023421 ACA 20251231C264.4AC30.2 202272ProBio CaymanProBio Cayman57,314,000B37.3202276202274202276 B 管理層討論及分析 202352637,609,0705.3250.035.210.4168%A202352620235282023625 A 20251231B1.644.12.9A41.82.7 3.061.9 532.4173.8230.3 202410222024101810 30 管理層討論及分析 20251231536.820241231518.03.6% 20251231812.02024719.931.1202417.9 20251231102024577.6541.1483.0 管理層討論及分析 202512311.520241.118.3%202418.1% 325.5 172.0(i)83.9(ii)74.6(iii)7.4 144.9(i)225.1(ii)85.7(iii)9.0(iv)6.0 1.782.2 管理層討論及分析 於關鍵聯營公司的重大投資 202512313163.0%47.18% 320.4398.1 CARVYKTI@1118 於金融資產的重大投資 20251231 1.5%5.7%112025123120251231 (i)(ii) (a)20251231* **AB 14.07202512315.0%14 10.26.5 管理層討論及分析 2025123112174.32.1%2.3%267.438.0 20251231143.320.40.65%1.2% 20251231 20251231 2025123130.8(i)12.1(ii)13.0(iii)4.0(iv)1.6(v)0.1 20251231223.331.8B202274ProBioCayman2022629202274 20251231 管理層討論及分析 2025HopewellGMP2026GMPCGTCGTmRNACAR-T(LNP)IITGMPNME(CD3)(VHH)T(TCE) AI IT 20251231 管理層討論及分析 20191 20251231202412318.2 20251231492.3 502.5 管理層討論及分析 (i)關稅及進出口條例變化 (ii)出口管制和經濟制裁 202525ESG 20251231283.6(i)(ii)(iii)PD-1PD-1PD-1/VEGFLM-299LM-29920241115202563020251014 管理層討論及分析 CGTAIAICRDMO2025 2002100250,000CGTAI 2024CRDMO20252025CRDMO20262025CAR-TCAR-TCGT CRDMOIIT 管理層討論及分析 AIAI CGT AI 202512316,16511% 管理層討論及分析 300.344.5% 2015715201512720246212019322201920246212025121520218232021202252620246212025121520192021 202183ProBio Cayman 董事及高級管理層 572015824202011222010420171212019123120201120201122Probio Technology I LimitedProBio CaymanProbioTechnology (BVI) LimitedProbio Technology HK Limited 董事及高級管理層 30199071997101999120005200052004720049200712†(Saint Gobain Grains and Powder Division)2008320103Quay Magnesium 19907202210†(Queen’s University) 6120155212015202220225220221217GS CorpGenScript Bioscience (BVI) LimitedGenscript USA IncorporatedGenScript USA Holding, Inc.CustomArray,Inc.GenScript (Hong Kong) Limited GenScript Biotech (Singapore) Pte. Ltd.GenScript Biotech (Netherlands)B.V.Genscript Biotech (Spain)S.L.Bestzyme Biotech LimitedBestzyme USA Inc.BestzymeBiotech HK LimitedBestzyme Hongkong Limited Bestzyme Biotech Inc.Yangtze Investment (BVI) LimitedYangtze Investment USA, Inc.Yangtze Holdings (BVI) Limited Yangtze Investment (HK) Limited CuregeneBiotech CorporationCuregene Biotech (BVI) LimitedCuregene Biotech (HK) LimitedProBio CaymanESG202488StarLand Capital Inc. 2019952002†(Schering-Plough)G200120022020820228 198471987719959†(Duke University) 董事及高級管理層 7620103201722017220197201971620201121202011222025430GenScript Diagnostics CorporationGenScript Diagnostics (BVI) Inc.GenScript Diagnostics HK Limited Probio Technology I Limited ProbioTechnology (BVI) LimitedProbio Technology HK LimitedProBio Inc.2024121ProBio Cayman 1990120003Clontech Laboratories, Inc.Gene